Results 131 to 140 of about 9,302 (232)

A FAERS pharmacovigilance analysis of dementia-related adverse event reports. [PDF]

Medicine (Baltimore)
Tao T, Liu B, Tao C, Chen W, Li R, Mao S, Wang K, Zhou M, Liu X.   +8 more
europepmc   +1 more source

Drug spectrum and disproportionality signals for diabetes insipidus in FAERS: multi-method analysis, JADER cross-database assessment, and PubMed-based case-level evidence. [PDF]

Front Pharmacol
Li Y, Zhou Y, Tian J, Wei D, Bi X, Liu H, Yang L.   +6 more
europepmc   +1 more source

Safety assessment of ambrisentan based on the FDA Adverse Event Reporting System. [PDF]

Medicine (Baltimore)
Dan Y, Xu G, Chen H, Li H, Hu B.
europepmc   +1 more source

Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System. [PDF]

Mayo Clin Proc Innov Qual Outcomes
Elsallab M, Lunning M, Ellithi M, Toron F, Braun R, Wang L, Wang P, Jones M, Maus MV.   +8 more
europepmc   +1 more source

Disproportionate reporting of euglycaemic and diabetic ketoacidosis with SGLT-2 inhibitors across expanding cardiorenal indications: a cross-database study of FAERS and JADER. [PDF]

Front Endocrinol (Lausanne)
Chen J, Wang D, Duan X, Wang J, Zhao Z, Xing X.   +5 more
europepmc   +1 more source